Repligen Co. (NASDAQ:RGEN) Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC lowered its holdings in Repligen Co. (NASDAQ:RGEN) by 5.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,237 shares of the biotechnology company’s stock after selling 867 shares during the period. Yousif Capital Management LLC’s holdings in Repligen were worth $2,337,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in RGEN. Champlain Investment Partners LLC grew its position in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the last quarter. DF Dent & Co. Inc. boosted its stake in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares in the last quarter. Two Sigma Advisers LP grew its holdings in shares of Repligen by 421.9% in the 3rd quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after acquiring an additional 102,100 shares during the last quarter. Fred Alger Management LLC raised its position in shares of Repligen by 29.5% during the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after purchasing an additional 90,831 shares during the period. Finally, First Turn Management LLC purchased a new stake in shares of Repligen during the third quarter valued at $13,202,000. 97.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

RGEN has been the topic of several recent analyst reports. Wolfe Research assumed coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. HC Wainwright cut their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Finally, TD Cowen assumed coverage on Repligen in a research report on Monday. They issued a “buy” rating and a $200.00 target price for the company. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $186.00.

Repligen Trading Down 1.4 %

Shares of NASDAQ RGEN opened at $153.86 on Tuesday. The business has a 50 day simple moving average of $155.37 and a 200 day simple moving average of $148.93. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13. The stock has a market cap of $8.62 billion, a price-to-earnings ratio of -415.83, a PEG ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.23 earnings per share. On average, research analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.